Alkermes Plc (NASDAQ:ALKS) insider Shane Cooke sold 6,207 shares of the business’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $60.22, for a total value of $373,785.54. Following the completion of the transaction, the insider now directly owns 80,915 shares of the company’s stock, valued at approximately $4,872,701.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Alkermes Plc (NASDAQ ALKS) traded down $2.14 during trading on Tuesday, hitting $56.57. The company’s stock had a trading volume of 1,268,300 shares, compared to its average volume of 933,940. The company has a market cap of $8,700.00, a P/E ratio of -50.96 and a beta of 2.13. Alkermes Plc has a 1-year low of $46.42 and a 1-year high of $63.40. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Thursday, October 26th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.04. The business had revenue of $217.40 million during the quarter, compared to the consensus estimate of $231.29 million. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The business’s quarterly revenue was up 20.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.09) EPS. equities research analysts forecast that Alkermes Plc will post -0.59 EPS for the current fiscal year.

A number of equities analysts have weighed in on the company. Credit Suisse Group decreased their target price on Alkermes from $70.00 to $66.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. Barclays set a $50.00 target price on Alkermes and gave the stock a “hold” rating in a research report on Thursday, October 26th. Citigroup set a $62.00 target price on Alkermes and gave the stock a “hold” rating in a research report on Thursday, October 26th. Zacks Investment Research raised Alkermes from a “hold” rating to a “buy” rating and set a $61.00 target price for the company in a research report on Monday, January 8th. Finally, BidaskClub raised Alkermes from a “sell” rating to a “hold” rating in a research report on Wednesday, December 27th. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Alkermes has a consensus rating of “Hold” and a consensus target price of $63.33.

Several institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its stake in shares of Alkermes by 0.4% during the 2nd quarter. FMR LLC now owns 22,978,575 shares of the company’s stock valued at $1,332,068,000 after acquiring an additional 96,457 shares during the period. Vanguard Group Inc. grew its stake in shares of Alkermes by 3.7% during the 2nd quarter. Vanguard Group Inc. now owns 12,546,198 shares of the company’s stock valued at $727,303,000 after acquiring an additional 449,563 shares during the period. Woodford Investment Management Ltd grew its stake in shares of Alkermes by 2.4% during the 2nd quarter. Woodford Investment Management Ltd now owns 7,647,977 shares of the company’s stock valued at $443,353,000 after acquiring an additional 177,449 shares during the period. Thornburg Investment Management Inc. grew its stake in shares of Alkermes by 39.8% during the 3rd quarter. Thornburg Investment Management Inc. now owns 2,779,364 shares of the company’s stock valued at $141,303,000 after acquiring an additional 790,692 shares during the period. Finally, Janus Henderson Group PLC grew its stake in shares of Alkermes by 13.7% during the 3rd quarter. Janus Henderson Group PLC now owns 2,650,006 shares of the company’s stock valued at $134,726,000 after acquiring an additional 319,014 shares during the period. Institutional investors and hedge funds own 99.66% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Alkermes Plc (ALKS) Insider Shane Cooke Sells 6,207 Shares” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/16/alkermes-plc-alks-insider-shane-cooke-sells-6207-shares.html.

About Alkermes

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.